

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/004,422	12/06/2001	Anuschirwan Peyman	02481.1773	8208	
5487	7590 05/27/2004		EXAMINER		
ROSS J. OEHLER			CHANG, CELIA C		
AVENTIS PHARMACEUTICALS INC. ROUTE 202-206			ART UNIT	PAPER NUMBER	
MAIL CODE: D303A			1625		
BRIDGEWA	TER, NJ 08807		DATE MAILED: 05/27/200-	DATE MAILED: 05/27/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
Advisory Action	10/004,422	PEYMAN ET AL.					
Advisory Action	Examiner	Art Unit					
	Celia Chang	1625					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
THE REPLY FILED FAILS TO PLACE THIS APP Therefore, further action by the applicant is required to ave final rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appea Examination (RCE) in compliance with 37 CFR 1.114.) a timely filed amendment which	ation. A proper reply h places the applica	ition in				
PERIOD FOR RE	PLY [check either a) or b)]						
a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Offictimely filed, may reduce any earned patent term adjustment. See 37 CFR 1.17(a) is calculated from:	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF THE date on which the petition under 37 CF of extension and the corresponding amount the shortened statutory period for reply be later than three months after the main	g date of the final rejecting HE FINAL REJECTION. R 1.136(a) and the approper the final representation of the fee. The appropriginally set in the final	on. See MPEP opriate extension ropriate extension Office action; or				
 1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal. 2. The proposed amendment(s) will not be entered because: 							
• •		see NOTE below):					
(a) they raise new issues that would require further consideration and/or search (see NOTE below);							
(b) they raise the issue of new matter (see Note below);							
(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or							
(d) they present additional claims without canceling a corresponding number of finally rejected claims.							
NOTE: <u>see attachment</u> .							
3. Applicant's reply has overcome the following reject		e de la Alemanda de Cilenda					
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).							
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because:							
6. The affidavit or exhibit will NOT be considered becarised by the Examiner in the final rejection.	ause it is not directed SOLELY t	to issues which wer	e newly				
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we	t(s) a) will not be entered or bould be rejected is provided belo)∭ will be entered a ow or appended.	and an				
The status of the claim(s) is (or will be) as follows:							
Claim(s) allowed:							
Claim(s) objected to:							
Claim(s) rejected: <u>8-26</u> .							
Claim(s) withdrawn from consideration:							
8. The drawing correction filed on is a) app	roved or b)☐ disapproved by t	the Examiner.					
9. Note the attached Information Disclosure Stateme	nt(s)(PTO-1449) Paper No(s)	·					
10. Other:							
		CEILA CHANG PRIMARY EXAMIN GROUP-1200					

Page 2

Application/Control Number: 10/004,422

Art Unit: 1625

--ATTACHMENT TO ADVISORY—

Applicants' amendment to the specification and claims would not be entered as containing NEW MATTER for the following reason:

- 1. The amendment of the specification in R20, $C\alpha 1$ and $C\alpha 2$ lacks antecedent basis in the specification.
- 2. The interpretation of the newly added structure wherein R20 is C3 alkyl at least one carbon is replaced with nitrogen, sulfur or oxygen etc. lacks any descriptive basis since no description to such structure in the central ring moiety corresponding to this newly inserted concept can be found. Please note that the "Het" group defined a mono-or bicyclic 5- to 10 membered heterocyclic groups with examples listed on pages 18-20. Please note that such description while support the "named" moieties one at a time does not provide descriptive support for the instant amendment wherein the ring is unsaturated and the substituents are at the particular position (please note that the bonding at least for nitrogen containing rings can be through any atom even nitrogen). Therefore, the newly amended description, although more limiting, created new "concept" not specifically described in the specification as originally filed. Especially, applicants' argument with respect to art rejection particularly related to "position" of substitution.
- 3. Not only the claims are drawn to new matter based on newly created concepts not found in the description as originally filed, the claims being drawn to treating inflammatory response, inflammation, cardiovascular disorder, etc. with an anti factor Xa compounds are still under the 112 second and first paragraph rejections which must be maintained.